EHA 2019 | Why does FLT3 testing need to be performed?


At the 24th Congress of the European Hematology Association (EHA), Jorge Sierra from Hospital de la Santa Creu i Sant Pau, Barcelona, ES, talks about the need to perform FLT3 testing in patients with AML.
Jorge Sierra describes how FLT3 mutations are one of the most common molecular abnormalities in acute myeloid leukemia (AML). He stresses the importance of testing patients for FLT3 mutations because there are FLT3-targeting agents available, such as midostaurin, and because the presence of FLT3 internal tandem duplication (FLT3-ITD) confers an adverse prognosis.